HIK Hikma Pharmaceuticals PLC

22.22USD1687.00 GBp · LSE+0.12%Mkt Cap: 4.60B USDP/E: 12.88

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. Th…

Insiders, last 90 days1 buy
Institutional holders11 on file

Key Statistics

Company
Market Cap4.60B USD
Enterprise Value7.02B USD
Revenue (TTM)3.42B USD
Gross Profit1.44B USD
Net Income (TTM)402.00M USD
Revenue/Share15.64 USD
Last Price22.22 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.5K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINGB00B0LCW083
Valuation
P/E (Trailing)12.88
P/E (Forward)9.18
PEG1.71
EV/EBITDA6.07
EV/Revenue2.05
P/S1.02
P/B1.94
EPS (TTM)1.31 USD
EPS (Forward)1.84 USD
52W Range
15.6387% of range23.20
52W High23.20 USD
52W Low15.63 USD
Profitability
Gross Margin43.03%
Oper. Margin19.89%
EBITDA Margin25.71%
Profit Margin12.00%
ROE15.50%
ROA7.09%
ROIC12.51%
ROCE15.01%
Growth
Revenue Growth4.20%
Earnings Growth-4.70%
Cash Flow & Leverage
Operating CF436.00M USD
CapEx (TTM)317.00M USD
FCF Margin0.42%
FCF Yield0.31%
Net Debt1.67B USD
Net Debt/EBITDA1.90
Net Debt/FCF116.03
Balance Sheet
Debt/Equity0.62
Current Ratio1.98
Quick Ratio1.02
Book Value/Sh8.70 USD
Cash/Share1.33 USD
Dividends
Fwd Div Rate0.0084 USD
Trail. Div Rate0.01 USD
Div. Yield3.82%
5Y Avg Yield2.85%
Payout Ratio47.32%
Ex-Div DateAug 13, 2026
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)26.73 USD
Upside (mean)+20.3%
Target Range22.82 USD – 35.51 USD
22.82+20.3% to mean35.51
# Analysts12
Ownership
Shares Out.206.97M
Float145.38M
Insiders32.36%
Institutions40.84%
Technical
SMA 5021.49 (+3.4%)
SMA 20019.86 (+11.8%)
Beta0.62
S&P 52W Chg12.08%
Avg Vol (30d)531.94K
Avg Vol (10d)712.88K
Technical Indicators
RSI (14)54.3
MACD5.1998
MACD Signal8.3015
MACD Hist.-3.1018
BB Upper23.32 USD
BB Middle22.23 USD
BB Lower21.13 USD
BB Width9.86%
ATR (14)0.5857 USD
Vol Ratio (20d)0.56x

About Hikma Pharmaceuticals (LON: HIK)

›

Hikma Pharmaceuticals (LON: HIK) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 9,500 employees.

The shares were at 1687.00 GBp on 19 November 2026, up 7.0% over 52 weeks. Its 52-week range is 1187.00 GBp to 1762.00 GBp: the price is 4.3% below the high and 42.1% above the low.

At a market capitalisation of 3.49B GBP, it trades at 12.9 times trailing earnings and 9.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 48% for HIK. It pays a dividend yielding 3.82% (it pays out 47% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Hikma Pharmaceuticals reports return on equity of 15.5%, an operating margin of 19.9% and revenue up 4.2% year over year.

Its debt exceeds its cash by 1.67B USD, a debt-to-equity ratio of 0.62. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 2030.01 GBp is 20.3% above the current price. The next earnings report is expected on 25 February 2027.